Financial news, mergers and acquisitions, partnerships, and alliances.
FDA Delays Decision for Sarepta Therapeutics Duchenne Muscular Dystrophy Gene Therapy
According to Sarepta, the federal agency has indicated it may grant accelerated approval to SRP-9001 as a treatment for a subgroup of patients based on age.
PTC Therapeutics Cuts Multiple Gene Therapy Programs
The company, which focuses on rare disease gene therapies and small molecule treatments, also said its CFO will leave the firm.
Checkpoint Therapeutics Announces $10M Registered Direct Offering of Common Stock
The company will use the funds to support the manufacturing and pre-commercial activities for its lead candidate cosibelimab.
Theralink to Become Subsidiary of IMAC via Stock-for-Stock Reverse Merger
Theralink will become a wholly owned subsidiary of IMAC focused on proteomic testing for guiding cancer therapy and drug development.
Quanta Therapeutics Raises $50.7M in Series D Financing
The firm anticipates starting proof-of-concept clinical studies for its two lead KRAS inhibitors by the end of 2024.